Table 2.
Treatment-related adverse events in the patients
| All treated patients (n = 6) | ||
|---|---|---|
| Grade 1–2 | Grade 3–4 | |
| Constitutional | ||
| Injection-site reaction | 6 (100%) | 0 |
| Flu-like symptoms | 0 | 0 |
| Fever | 0 | 0 |
| Fatigue | 0 | 0 |
| Chills | 0 | 0 |
| Dizziness | 0 | 0 |
| Gastrointestinal | ||
| Nausea | 0 | 0 |
| Constipation | 0 | 0 |
| Vomiting | 0 | 0 |
| Diarrhea | 0 | 0 |
| Dry mouth | 0 | 0 |
| Respiratory | ||
| Cough | 0 | 0 |
| Dyspnea | 0 | 0 |
| Laboratory | ||
| Anemia | 0 | 0 |
| Neutropenia | 0 | 0 |
| Other | ||
| Rash | 1(16.7%) | 0 |
| Headache | 1(16.7%) | 0 |
*Including all patients who received at least one dose of trial treatment